

INNOVATION IN THE DELIVERY OF INHALED NITRIC OXIDE

GENOSYL® DELIVERY SYSTEM

SIMPLIFIED TANKLESS SOLUTION

GENOSYL® DS is the Only Device Approved to Accurately Deliver iNO in Low-Flow Anesthesia

- Streamlines workflow – simple setup and initiation, proven to be able to be completed by Anesthesia providers
- Supports physician's preference – no need to change practice to deliver iNO
- Approved for use with low-flow anesthesia, which:
 - Maintains body temperature, and reduce water loss, which may prevent postoperative complications (e.g.: hypothermia, pneumonia, etc)¹
 - Decreases the amount of anesthetic agents used, thereby reducing cost^{2,3}
 - Reduces greenhouse gas emissions by cutting the amount of unused anesthetics agents release into environment⁴



1. Bilgi M, Goksu S, Mizrak A, Cevik C, Gul R, Koruk S, Sahin L. Comparison of the effects of low-flow and high-flow inhalational anaesthesia with nitrous oxide and desflurane on mucociliary activity and pulmonary function tests. *European Journal of Anaesthesiology* 2011;28(4): 279-283.
2. Hayu AL, Hanindito E, Hamzah H, Utariani A. Effectiveness of high-flow inhalation anesthesia technique using isoflurane compared to low-flow inhalation anesthesia technique using sevoflurane and isoflurane in terms of cost and safety. *Bali J Anaesthesiol.* 2019;3:170-173.
3. Cotter SM, Petros AJ, Doré CJ, Barber ND, White DC. Low-flow anaesthesia. *Anaesthesia.* 1991;46:1009-1012.
4. Varughese S, Ahmed R. Environmental and occupational considerations of anesthesia: a narrative review and update.



MEDICAL INFORMATION



INVENTORY MANAGEMENT



TECHNICAL SUPPORT



TRAINING AND EDUCATION



Supporting innovation and change, our experienced, Registered RTs provide 24/7/365 support and a customized partnership to ensure success

- 24 hours a day, 7 days a week, 365 days a year
- Distribution centers nationwide
- Over 2 million patient hours

EVERY DAY. EVERY HOUR. EVERY MINUTE.

For more information, contact your VERO Biotech Representative or the Partnership365™ Care Team at **vero-biotech.com** or **1.877.337.4118**

INDICATION AND IMPORTANT SAFETY INFORMATION

GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

- GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
- Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
- Methemoglobin, NO₂, and PaO₂ should be monitored during nitric oxide administration.
- In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema.
- The most common adverse reaction is hypotension.
- Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
- GENOSYL must be administered using a calibrated GENOSYL Delivery System. Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
- NO₂, nitric dioxide; OR, operating room; PaO₂, partial pressure of oxygen.